The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes.

PubWeight™: 5.19‹?› | Rank: Top 1%

🔗 View Article (PMID 6723384)

Published in Chest on June 01, 1984


D A Mahler, D H Weinberg, C K Wells, A R Feinstein

Articles citing this

(truncated to the top 100)

A measure of quality of life for clinical trials in chronic lung disease. Thorax (1987) 10.87

Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA (2003) 7.01

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax (2003) 4.53

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med (2007) 2.86

Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med (2007) 2.41

The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18

Quality of life measurement for patients with diseases of the airways. Thorax (1991) 1.88

Evaluation of three scales of dyspnea in chronic obstructive pulmonary disease. Ann Thorac Med (2009) 1.85

Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med (2012) 1.80

Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax (2006) 1.76

Measuring quality of life in clinical trials: a taxonomy and review. CMAJ (1989) 1.73

Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med (2003) 1.70

Pulmonary rehabilitation in chronic respiratory insufficiency. 7. Health-related quality of life among patients with chronic obstructive pulmonary disease. Thorax (1994) 1.63

Multidimensional Dyspnea Profile: an instrument for clinical and laboratory research. Eur Respir J (2015) 1.56

Airway count and emphysema assessed by chest CT imaging predicts clinical outcome in smokers. Chest (2010) 1.52

Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. Thorax (1994) 1.51

Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis (2012) 1.47

Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest (2012) 1.44

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis (2014) 1.34

Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res (2010) 1.31

Heterogeneity of pulmonary perfusion as a mechanistic image-based phenotype in emphysema susceptible smokers. Proc Natl Acad Sci U S A (2010) 1.31

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res (2010) 1.21

Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis (2009) 1.19

Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? Int J Chron Obstruct Pulmon Dis (2006) 1.18

Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis (2007) 1.15

Long-term results of diaphragmatic plication in adults with unilateral diaphragm paralysis. J Cardiothorac Surg (2010) 1.15

Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax (2010) 1.14

End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol (2009) 1.13

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res (2014) 1.12

Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest (2009) 1.12

The severity of airways obstruction as a determinant of treatment response in COPD. Int J Chron Obstruct Pulmon Dis (2006) 1.11

New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol (2015) 1.10

Quality of life in the first 100 days after suspected acute myocardial infarction--a suitable trial endpoint? J Epidemiol Community Health (1992) 1.07

Systems for lung volume standardization during static and dynamic MDCT-based quantitative assessment of pulmonary structure and function. Acad Radiol (2012) 1.04

Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest (2010) 1.04

Association between airway caliber changes with lung inflation and emphysema assessed by volumetric CT scan in subjects with COPD. Chest (2011) 1.03

Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respir Res (2010) 1.02

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med (2016) 1.01

Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis (2008) 1.01

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res (2011) 1.01

Development of a Barthel Index based on dyspnea for patients with respiratory diseases. Int J Chron Obstruct Pulmon Dis (2016) 1.01

Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol (2004) 1.01

The Breathe Easier through Weight Loss Lifestyle (BE WELL) Intervention: a randomized controlled trial. BMC Pulm Med (2010) 1.00

Physical activity among lung cancer survivors: changes across the cancer trajectory and associations with quality of life. Cancer Epidemiol Biomarkers Prev (2009) 1.00

Role of tiotropium in the treatment of COPD. Int J Chron Obstruct Pulmon Dis (2007) 0.99

Self-efficacy and health status in patients with coronary heart disease: findings from the heart and soul study. Psychosom Med (2007) 0.98

Pulmonary function tests: are they really necessary? Can Fam Physician (1989) 0.97

Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. Rheumatology (Oxford) (2009) 0.97

Efficacy of two educational interventions about inhalation techniques in patients with chronic obstructive pulmonary disease (COPD). TECEPOC: study protocol for a partially randomized controlled trial (preference trial). Trials (2012) 0.97

Fatigue and functional impairment in early-stage non-small cell lung cancer survivors. J Pain Symptom Manage (2011) 0.96

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis (2007) 0.95

Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. Ann Epidemiol (2010) 0.95

Current dyspnea among long-term survivors of early-stage non-small cell lung cancer. J Thorac Oncol (2010) 0.94

Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med (2013) 0.94

Interstitial lung disease in systemic sclerosis. Lung (2007) 0.94

Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respir Med (2010) 0.93

Measures of dyspnea in pulmonary rehabilitation. Multidiscip Respir Med (2010) 0.93

Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax (1995) 0.92

Health-related quality of life among early-stage, non-small cell, lung cancer survivors. Lung Cancer (2010) 0.91

Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance. Int J Chron Obstruct Pulmon Dis (2008) 0.91

Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry. Thorax (2006) 0.89

Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol (2011) 0.89

Analysis of longitudinal changes in dyspnea of patients with chronic obstructive pulmonary disease: an observational study. Respir Res (2012) 0.88

The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes (2014) 0.87

Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax (1993) 0.87

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther (2014) 0.87

Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res (2012) 0.87

The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study. BMC Pulm Med (2012) 0.87

Indacaterol: a comprehensive review. Int J Chron Obstruct Pulmon Dis (2013) 0.86

Health-related quality of life in emphysema. Proc Am Thorac Soc (2008) 0.86

End points for comparative effectiveness research in heart failure. Heart Fail Clin (2012) 0.85

Effects of 3-week outpatient pulmonary rehabilitation on exercise capacity, dyspnea, and quality of life in COPD. Lung (2008) 0.85

Airflow limitation or static hyperinflation: which is more closely related to dyspnea with activities of daily living in patients with COPD? Respir Res (2011) 0.85

The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies. Respir Res (2016) 0.85

Mechanical ventilatory constraints during incremental cycle exercise in human pregnancy: implications for respiratory sensation. J Physiol (2008) 0.85

Quality of life in lung transplantation. Semin Respir Crit Care Med (2013) 0.85

Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE study. Int J Chron Obstruct Pulmon Dis (2015) 0.84

Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.84

Long-term efficacy of intensive cycle ergometer exercise training program for advanced COPD patients. Int J Chron Obstruct Pulmon Dis (2015) 0.83

Barriers associated with reduced physical activity in COPD patients. J Bras Pneumol (2014) 0.83

Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. Curr Rheumatol Rev (2010) 0.82

Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int J Chron Obstruct Pulmon Dis (2011) 0.82

Evaluation of quality of life with the chronic obstructive pulmonary disease assessment test in chronic obstructive pulmonary disease and the effect of dyspnea on disease-specific quality of life in these patients. Yonsei Med J (2013) 0.82

Tiotropium bromide: an update. Open Respir Med J (2009) 0.82

A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges. Int J Chron Obstruct Pulmon Dis (2015) 0.81

Predictors of health status do not change over three-year periods and exacerbation makes difference in chronic obstructive pulmonary disease. Health Qual Life Outcomes (2011) 0.81

Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BMC Pulm Med (2014) 0.81

Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. Diabetes Care (2008) 0.81

The continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trial. PLoS One (2014) 0.81

Relationship between BODE index, quality of life and inflammatory cytokines in COPD patients. Multidiscip Respir Med (2010) 0.81

Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease. J Thorac Dis (2013) 0.81

Cluster Analysis in Patients with GOLD 1 Chronic Obstructive Pulmonary Disease. PLoS One (2015) 0.80

The association between forced expiratory volume in one second (FEV1) and pulse oximetric measurements of arterial oxygen saturation (SpO2) in the patients with COPD: A preliminary study. J Res Med Sci (2014) 0.80

Delayed diagnosis of sarcoidosis is common in Brazil. J Bras Pneumol (2013) 0.80

Clinical diaries in COPD: compliance and utility in predicting acute exacerbations. Int J Chron Obstruct Pulmon Dis (2012) 0.80

Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J (2009) 0.80

Association of depression with disease severity in patients with chronic obstructive pulmonary disease. Lung (2014) 0.80

Evaluation of the psychometric properties of the Nighttime Symptoms of COPD Instrument. Int J Chron Obstruct Pulmon Dis (2015) 0.79

The clinical COPD questionnaire correlated with BODE index-A cross-sectional study. ScientificWorldJournal (2012) 0.79

Impact of symptom burden in post-surgical non-small cell lung cancer survivors. Support Care Cancer (2013) 0.79

Articles by these authors

A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol (1996) 20.25

Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med (1978) 11.42

A critical appraisal of the quality of quality-of-life measurements. JAMA (1994) 9.10

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med (1985) 8.55

High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol (1990) 8.28

Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther (1981) 7.33

Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol (1995) 6.94

The risk of determining risk with multivariable models. Ann Intern Med (1993) 6.45

Variability in radiologists' interpretations of mammograms. N Engl J Med (1994) 5.96

Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA (1995) 5.94

Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J (2002) 4.68

Evaluation of clinical methods for rating dyspnea. Chest (1988) 4.12

Spectrum bias in the evaluation of diagnostic tests: lessons from the rapid dipstick test for urinary tract infection. Ann Intern Med (1992) 3.64

Academic calculations versus clinical judgments: practicing physicians' use of quantitative measures of test accuracy. Am J Med (1998) 3.36

Problems of comorbidity in mortality after prostatectomy. JAMA (1992) 3.27

The International Health Program: the fifteen-year experience with Yale University's Internal Medicine Residency Program. Am J Trop Med Hyg (1999) 3.23

Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA (1999) 3.07

An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA (1979) 3.03

The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis (1974) 3.01

The large, oxygen-rich halos of star-forming galaxies are a major reservoir of galactic metals. Science (2011) 2.95

Identification of cellular proteins required for simian virus 40 DNA replication. J Biol Chem (1989) 2.84

A cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus type 2. Proc Natl Acad Sci U S A (1983) 2.83

The BCG controversy. A methodological and statistical reappraisal. JAMA (1983) 2.60

Adenoviral early region 4 is required for efficient viral DNA replication and for late gene expression. J Virol (1986) 2.54

Clinical biostatistics. XXXVII. Demeaned errors, confidence games, nonplussed minuses, inefficient coefficients, and other statistical disruptions of scientific communication. Clin Pharmacol Ther (1976) 2.53

An analysis of diagnostic reasoning. 3. The construction of clinical algorithms. Yale J Biol Med (1974) 2.44

Context bias. A problem in diagnostic radiology. JAMA (1996) 2.42

Scientific and clinical problems in indexes of functional disability. Ann Intern Med (1986) 2.41

The qualification period. J Clin Epidemiol (1991) 2.33

Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol (1995) 2.32

A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med (1990) 2.32

Clinical biostatistics. 8. An analytic appraisal of the University Group Diabetes Program (UGDP) study. Clin Pharmacol Ther (1971) 2.28

Claims of equivalence in medical research: are they supported by the evidence? Ann Intern Med (2000) 2.27

Coding ordinal independent variables in multiple regression analyses. Am J Epidemiol (1987) 2.15

Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med (2000) 2.13

A new prognostic staging system for the acquired immunodeficiency syndrome. N Engl J Med (1989) 2.10

Methodologic standards and contradictory results in case-control research. Am J Med (1979) 2.09

Clinical biostatistics. XLIV. A survey of the research architecture used for publications in general medical journals. Clin Pharmacol Ther (1978) 2.07

T. Duckett Jones Memorial Lecture. The Jones criteria and the challenges of clinimetrics. Circulation (1982) 2.06

Clinical biostatistics. XLI. Hard science, soft data, and the challenges of choosing clinical variables in research. Clin Pharmacol Ther (1977) 2.04

The impact of ethnicity, family income, and parental education on children's health and use of health services. Am J Public Health (1999) 2.02

A collection of 56 topics with contradictory results in case-control research. Int J Epidemiol (1988) 2.02

A new clinical prognostic staging system for acute pancreatitis. Am J Med (1993) 2.02

Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest (2001) 2.01

The 'chagrin factor' and qualitative decision analysis. Arch Intern Med (1985) 1.94

Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study. Lancet (1979) 1.92

An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med (1983) 1.87

Clinical biostatistics. XXV. A survey of the statistical procedures in general medical journals. Clin Pharmacol Ther (1974) 1.87

Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J (2003) 1.84

Double standards, scientific methods, and epidemiologic research. N Engl J Med (1982) 1.81

Clinical biostatistics. XXXIX. The haze of Bayes, the aerial palaces of decision analysis, and the computerized Ouija board. Clin Pharmacol Ther (1977) 1.80

Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest (2001) 1.73

An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity. JAMA (1979) 1.65

Indexes and boundaries for "quantitative significance" in statistical decisions. J Clin Epidemiol (1990) 1.63

Measurement of lower limb alignment using long radiographs. J Bone Joint Surg Br (1991) 1.58

Current problems and future challenges in randomized clinical trials. Circulation (1984) 1.57

Dyspnea ratings for prescription of cross-modal exercise in patients with COPD. Chest (1998) 1.54

An analysis of Berkson's bias in case-control studies. J Chronic Dis (1986) 1.53

Clinical biostatistics XXXI. On the sensitivity, specificity, and discrimination of diagnostic tests. Clin Pharmacol Ther (1975) 1.52

Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis (1970) 1.51

Complications of peripheral arteriography: a new system to identify patients at increased risk. J Vasc Surg (1995) 1.50

The problems of the "problem-oriented medical record". Ann Intern Med (1973) 1.50

Clinical biostatistics. XX. The epidemiologic trohoc, the ablative risk ratio, and "retrospective" research. Clin Pharmacol Ther (1973) 1.50

The role of diagnostic inconsistency in changing rates of occurrence for coronary heart disease. J Clin Epidemiol (1992) 1.50

On white-coat effects and the electronic monitoring of compliance. Arch Intern Med (1990) 1.48

Joseph Goldberger: an unsung hero of American clinical epidemiology. Ann Intern Med (1994) 1.47

A bibliography of publications on observer variability (final installment). J Clin Epidemiol (1992) 1.47

An analysis of diagnostic reasoning. I. The domains and disorders of clinical macrobiology. Yale J Biol Med (1973) 1.47

Clinical utility of endoscopic retrograde cholangiopancreatography. Gastrointest Endosc (1997) 1.45

Bootstraps and jackknives: new, computer-intensive statistical tools that require no mathematical theories. J Investig Med (1998) 1.43

An additional basic science for clinical medicine: IV. The development of clinimetrics. Ann Intern Med (1983) 1.43

Discontinuation of antistreptococcal prophylaxis. A double-blind study in rheumatic patients free of heart disease. JAMA (1966) 1.42

A critique of methodology in studies of anticoagulant therapy for acute myocardial infarction. N Engl J Med (1969) 1.42

The problem of "protopathic bias" in case-control studies. Am J Med (1980) 1.41

On exorcizing the ghost of Gauss and the curse of Kelvin. MD Comput (1992) 1.39

Does diagnostic accuracy in mammography depend on radiologists' experience? J Womens Health (1998) 1.37

Coffee and pancreatic cancer. The problems of etiologic science and epidemiologic case-control research. JAMA (1981) 1.37

Clinical biostatistics. XXXIV. The other side of 'statistical significance': alpha, beta, delta, and the calculation of sample size. Clin Pharmacol Ther (1975) 1.36

The 'epidemiologic necropsy'. Unexpected detections, demographic selections, and changing rates of lung cancer. JAMA (1987) 1.35

Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. J Chronic Dis (1979) 1.34

New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association. JAMA (1989) 1.34

Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis (1981) 1.32

Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer (1996) 1.31

Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis (1985) 1.30

An additional basic science for clinical medicine: I. The constraining fundamental paradigms. Ann Intern Med (1983) 1.29

Clinical effects of recurrent attacks of acute rheumatic fever: a prospective epidemiologic study of 105 episodes. J Chronic Dis (1967) 1.28

Monte Carlo methods in clinical research: applications in multivariable analysis. J Investig Med (1997) 1.28

Operational criteria for adverse drug reactions in evaluating suspected toxicity of a popular scabicide. Clin Pharmacol Ther (1980) 1.27

Clinical biostatistics. XXVII. The derangements of the 'range of normal'. Clin Pharmacol Ther (1974) 1.27

Clinical biostatistics. II. Statistics versus science in design of experiments. Clin Pharmacol Ther (1970) 1.27